About the Authors
- Ann W. Walsh
-
Affiliation Research and Development, Bristol-Myers Squibb Inc., Wallingford, Connecticut, United States of America
- David R. Langley
-
* E-mail: david.langley@bms.com (DRL); daniel.tenney@bms.com (DJT)
Affiliation Research and Development, Bristol-Myers Squibb Inc., Wallingford, Connecticut, United States of America
- Richard J. Colonno
-
Current address: Presidio Pharmaceuticals, San Francisco, California, United States of America
Affiliation Research and Development, Bristol-Myers Squibb Inc., Wallingford, Connecticut, United States of America
- Daniel J. Tenney
-
* E-mail: david.langley@bms.com (DRL); daniel.tenney@bms.com (DJT)
Affiliation Research and Development, Bristol-Myers Squibb Inc., Wallingford, Connecticut, United States of America
Competing Interests
All authors were paid employees of Bristol-Myers Squibb at the time of the work and all hold stock or stock options in the company. Entecavir, the subject of the paper, is a marketed product of Bristol-Myers Squibb. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials in the paper, as detailed in the guide to authors.
Author Contributions
Conceived and designed the experiments: AWW DRL RJC DJT. Performed the experiments: AWW DRL. Analyzed the data: AWW DRL RJC DJT. Wrote the paper: AWW DRL RJC DJT.